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Abstract: Immune reactions inside the central nervous system are finely regulated, thanks to the presence of sev-
eral checkpoints that have the fundamental purpose to preserve this fragile tissue form harmful events. The cur-
rent knowledge on the role of neuroinflammation and neuro-immune interactions in the fields of multiple sclerosis, 
Alzheimer’s disease and Parkinson’s disease is reviewed. Moreover, a focus on the potential role of both active and 
passive immunotherapy is provided. Finally, we propose a common perspective, which implies that, under pathologi-
cal conditions, inflammation may exert both detrimental and protective functions, depending on local factors and 
the timing of immune activation and shutting-off systems.
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Introduction
The central nervous system (CNS) has been 
considered an immune privileged site for more 
than six decades, referring to its apparent 
inability to trigger adaptive immune reactions. 
However, this concept has undergone major re-
evaluation during the course of years and evi-
dence indicates there is still a lot to under-
stand. The CNS has peculiar characteristics 
which determine its status of privilege. Some of 
these are anatomical and include the presence 
of the blood-brain barrier (BBB), which assures 
separation between the nervous tissue and the 
peripheral environment. BBB is a physiological 
structure composed by endothelial tight junc-
tions around CNS capillaries supported by 
astrocytic ‘vascular feet’, which limits cellular 
and molecular migration towards the nervous 
parenchyma. The function of the BBB is there-
fore to maintain chemical balance within the 
CNS in order to support neuronal function [1] 
but also to limit penetration of antibodies and 
immune cells from the systemic circulation and 
any inflammatory reaction through the expres-
sion of transporters belonging to the superfami-
lies of ATP-binding cassette transporters (ABC-
transporters) and solute carriers (SLC) [2-4]. 
Another important anatomical condition sup-
porting the immune privilege of CNS is the lack 
of lymphatic tissue and conventional drainage 
in the context of the nervous parenchima for 
draining antigens and immune cells to periph-
eral lymph nodes [5]. From an immunological 
point of view, the CNS shows two crucial aspects 
which sustain such privilege: the relative lack of 
antigen presenting function and presence of an 
anti-inflammatory microenvironmental context. 
In peripheral sites, antigen presentation is nor-
mally carried out by professional antigen pre-
senting cells (APCs), comprising dendritic cells 
(DCs), which are the most potent APCs, macro-
phages and B cells. APCs trigger the adaptive 
immune response by collecting peptide anti-
gens, processing them and presenting them on 
MHC molecules to naive or memory T cells 
together with appropriate costimulatory signals 
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[6]. In order to exert their role, DCs have to 
migrate to the draining lymph nodes where T 
cells continuously recirculate [7]. Activated T 
cells then move to the site of infection where 
they exert their immunological function [8]. 
However, no parenchymal DC can be found in 
the healthy CNS [9]. The absence of inflamma-
tory mediators in CNS is important since they 
can alter the expression of protein transporters 
at the BBB; for example pro-inflammatory cyto-
kines such as IL-1β, IL-6 and TNF-α can alter 
the expression and activity of two ABC-
transporters i.e. the breast cancer resistance 
protein (BCRP or ABCG2) and P-glycoprotein 
(P-gp or ABCB1), as demonstrated by in vitro 
model of the human BBB [3]. Moreover, anoth-
er important aspect is the local production of 
anti-inflammatory mediators; TGF-β and IL-10 
are abundant in the CNS and promote, among 
their many functions, neuronal and glial surviv-
al [10-12]. 
The CNS seems therefore to constitute a com-
partment of its own. Just a small number of T 
lymphocytes are normally patrolling the CNS in 
absence of inflammation or injury although evi-
dence show that they can be recruited into the 
nervous parenchyma from the blood stream 
[13]. 
Despite initial observations, it has now become 
clear that inflammation does take place in neu-
rodegenerative diseases, but its role is still a 
matter of debate. Evidence has shown that the 
BBB is a ‘dynamic’ barrier, as its physical prop-
erties can be modulated by local secretion of 
cytokines and chemokines that induce adhe-
sion molecules allowing cellular traffic through 
post-capillary venules [14]. Furthermore, innate 
immune cells are present in the CNS and are 
represented by microglia and astrocytes. 
Microglia cells belong to the monocyte-macro-
phage system and colonize the CNS during 
embryonic development. In response to patho-
logical changes of the brain microenvironment, 
microglia can become ‘activated’ and prolifer-
ate, secrete cytokines, chemokines and other 
inflammation mediators. Once activated by 
INF-γ and other inflammatory mediators, these 
cells upregulate MHC class II complexes and 
become phagocytic [15-17], acting as a non-
professional APC. The role of microglia is con-
troversial in terms of neuroprotection and neu-
rodegeneration as evidence has been found in 
both directions. The dual activity of microglia 
appears to be linked to a change from an 
inflammatory (called M1) to an anti-inflammato-
ry phenotype (named M2); such change is 
mediated by interactions with other immune 
cells, including astrocytes and T lymphocytes 
[18]. Under physiological conditions, the inter-
action with astrocytes leads to a block of the 
microglial inflammatory response [19]. On the 
contrary, such mechanism could be impaired in 
inflammatory conditions where a down-regula-
tion of the astrocyte suppressive function may 
lead to microglial hyperactivation and conse-
quent release of pro-inflammatory cytokines 
[20]. The interaction with T cells is also impor-
tant in directing the fate of microglia, depend-
ing on the interaction with T cells secreting 
either pro-inflammatory (Th1) or anti-inflamma-
tory (Th2) cytokine patterns [21]. Certain cyto-
kines, such as IL-10, IL-4 and TGF-β, have anti-
inflammatory proterties and are able to 
enhance the neuroprotective role of microglia 
while others, such as IL-6 and TNF-α, have a 
pro-inflammatory activity [20, 22].
Astrocytes are a further type of resident cell 
population in the CNS. Like microglia, they are 
part of the glia whose main role is to support 
neurons in brain development and function. In 
response to inflammation or injury, astrocytes 
migrate and form a glial scar to protect the 
injured site. They can also secrete a set of 
immunoactive molecular mediators, including 
complement components, cytokines, and che-
mokines [1]. When activated, these cells upreg-
ulate MHC class II molecules but apparently 
are not able to function as APCs as they miss 
necessary co-stimulatory molecules [23]. 
However, studies have demonstrated that they 
can induce regulatory T cells in vitro, showing 
interesting protective influences in experimen-
tal disease-models [24]. While microglia and 
astrocytes display a close reciprocal communi-
cation, their influence on T cells in the CNS still 
has to be elucidated. Evidence has shown that 
CNS resident cells (and microglia in particular) 
can produce inflammatory mediators such as 
IL-23 and IL-1β that stimulate GM-CSF secre-
tion in CD4+ T helper cells (TH) [25, 26]. This 
molecule promotes recruitment of CD11b+ 
myeloid cells in the CNS, which is needed to 
sustain the inflammatory process [1]. Along 
with this, inflammatory mediators (cytokines, 
chemokines and matrix metalloproteinases) 
produced by activated T cells induce BBB dis-
ruption and facilitate CNS infiltration by periph-
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eral immune cells. Moreover, activated CD4+ T 
cells polarized towards the Th2 subset secrete 
IL-4 that sustains the B cell response.
Conflicting evidence supporting the importance 
of the immune response in neurodegneration 
come from epidemiological observations on 
the potential protective role of anti-inflammato-
ry drugs. By contrast, several reports suggest 
that immunotherapies stimulating the immune 
response may improve the outcome of neuro-
degenerative disease and that neurodegenera-
tive diseases may have a worse outcome in 
patients with different types of immunodefi-
ciencies [27].
Inflammation constitutes the body’s physiologi-
cal response that allows clearance of harmful 
agents and repair of injuries. Nevertheless, it 
can become potentially deleterious if excessive 
or deregulated. Probably, the CNS has the spe-
cial condition of immune privilege because of 
the poor regenerative potential of resident 
cells: a major inflammatory response can 
induce irreversible damage to neurons and oli-
godendrocytes. Neuronal loss is the common 
feature of neurodegenerative diseases and 
studies have shown that inflammation is a con-
stant element. The new concept of ‘neuroin-
flammation’ has emerged in the attempt to 
gather several pathological features shared by 
neurodegenerative disorders [28]. What is still 
to be understood is whether inflammatory reac-
tions are detrimental for the CNS or if they can 
be a valuable ally for treatment.
In the following sections, we will review the cur-
rent knowledge on neuroinflammation in three 
neurological conditions, multiple sclerosis (MS) 
Alzheimer’s disease (AD) and Parkinson’s dis-
ease (PD) focusing on both detrimental and 
protective aspects.
Multiple sclerosis (MS)
Multiple sclerosis (MS) certainly offers the best 
pathogenic paradigm to understand the com-
plex interplay between neuroinflammation and 
neurodegeneration. 
MS is an inflammatory demyelinating disease 
of the central nervous system (CNS) due to 
autoimmune aggression against myelin and 
neuronal antigens [29]. MS onset is usually 
between 20 and 40 years of age and, in most 
cases, the disease displays a chronic evolution 
leading to substantial disability [30]. Although 
MS aetiology remains unclear, evidence sup-
ports a role for both genetic and environmental 
predisposing factors, the latter being most like-
ly infectious agents acting through “molecular 
mimicry” [31]. The host defence system, repre-
sented in this case by T cells, can display cross 
reactivity between foreign antigens and self-
antigens. Autoreactive T cells are then able to 
migrate across the blood-brain barrier (BBB), 
infiltrate the CNS and finally orchestrate tissue 
damage [31]. Beside molecular mimicry, infec-
tions may also act through “bystander activa-
tion”, which assumes that the inflammation 
induced by the infectious agent functions as an 
adjuvant to promote the activation of autoreac-
tive T cells [32]. The two mechanisms are not 
mutually exclusive and may cooperate to induce 
the autoimmune disease and the epitope 
spreading of the autoimmune response [33]. 
Then, ‘pioneer’ autoimmune CD4+ T cells reach 
the CNS and produce cytokines, chemokines 
and other inflammatory agents inducing microg-
lia and astrocyte activation along with BBB dis-
ruption. This is followed by recruitment of the 
main mass of autoimmune T helper, T cytotoxic, 
and B lymphocytes causing development of the 
MS lesion. Recently, by using 2-photon imaging 
in vivo, it has been shown that T cell blasts gain 
the capacity to enter the CNS after residing 
transiently within the lung where they downreg-
ulate activation genes and upregulate genes 
involved in cell migration. Then, they move to 
the lung-associated lymphoid tissues before 
entering the blood circulation and reaching the 
CNS [34]. The further production of cytokines, 
reactive oxygen species, complement and anti-
bodies would determine myelin damage and 
possibly secondary axonal loss. The crucial role 
of the adaptive immune response is supported 
by the response that MS patients display to 
immunosuppressive and immunomodulating 
drugs [35]. 
Demyelination and axonal loss are the hall-
marks of MS. At macroscopic analysis, MS is 
characterized by demyelination plaques in the 
white matter. Microscopically, active lesions 
show inflammatory cell infiltrate, preponderant 
myelin damage with loss of oligodendrocytes 
and a minor but important component of axo-
nal loss. Over the years, most studies have 
been focused on the demyelinating process 
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rather that the axonal loss, but recent evidenc-
es support the possibility that neurodegenera-
tion is the key element of the clinical disability 
[36, 37]. However, the relationship between 
demyelination, neurodegeneration, and inflam-
mation is still controversial in MS. Two models 
have been proposed to explain the causal 
sequence of events. According to the outside-in 
model, demyelination leads to neurodegenera-
tion, whereas the inside-out model proposes 
that neuronal and axonal damage precedes 
demyelination [38]. The former model is sup-
ported by the picture displayed by mice immu-
nized with myelin oligodendrocyte glycoprotein 
(MOG) [39], the latter model by the picture dis-
played by mice immunized with neurofilament 
light protein (NF-L) [40].
Whatever is the starting event, the histological 
features of MS are those of chronic inflamma-
tion [41], that may be due to failure to clear a 
pathogenic “danger signal” leading to a persis-
tent inflammatory reaction supporting long-
term survival of immune cells. This support has 
been shown to depend on local production of 
pro-inflammatory cytokines (such as IL-1β, TNF, 
IL-6 and osteopontin) and pro-retention chemo-
kines by glial cells [42] and on impairment of 
apoptotic mechanisms [43]. Consistently, 
osteopontin (OPN ) levels are increased in the 
plasma and cerebrospinal fluid (CSF) of MS 
patients, particularly in the inflammatory phase 
of the disease and such increase is more strik-
ing during disease relapse than in remission 
[44, 45]. Furthermore, OPN gene variations 
associated to both increased protein levels and 
risk of MS development have been reported 
[46], and such gene variations increase the risk 
of disease progression and disability [47].
Within the pathogenic role of the adaptive 
immune response in MS, a key role is ascribed 
to cytotoxic T cells. Although T cells directed 
against myelin and neuronal antigens can be 
detected in healthy subjects [48], clonally 
expanded cytotoxic CD8+ T cells are the most 
represented population in the active lesions 
[49]. Evidence indicates that they have a role in 
neuronal loss as they can be observed in close 
contact with demyelinated axons, pointing their 
cytotoxic granules toward the axon [50]. 
Moreover, axonal damage seems to be mediat-
ed by perforin [51], whose secretion by CD8+ T 
cells is up-regulated in active multiple sclerosis 
lesions [52], and by the Fas/FasL system that is 
a further weapon used by cytotoxic cells [51]. In 
the Theiler’s virus encephalopathy model of 
MS, suppression of perforin expression pro-
tects mice from neuronal loss and neurological 
impairment, whereas demyelination is unaf-
fected [53, 54]. Moreover, lymphocytes infiltrat-
ing the brain may release tumor necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL) 
that leads to death of parenchymal cells 
through the interaction with TRAIL death recep-
tors expressed on these cells [55]. However, it 
must be underlined that cytotoxic cells may 
also play a protective role in MS, possibly 
through their activity as suppressor/regulator 
cells targeting and killing several immune cells 
involved in chronic inflammation. In line with 
this possibility, we previously reported that vari-
ations in the perforin gene (PRF1) may be a sus-
ceptibility factor for MS development [56] and a 
similar role may also be exerted by alterations 
decreasing the function of Fas [43, 57, 58]. 
Similar observations were also performed in 
other autoimmune diseases [59-63].
Autoantibodies (AutoAbs) may play a role in the 
pathogenesis of MS as well. This was firstly sug-
gested by the observation that oligoclonal 
immunoglobulins can be found in the patients’ 
CSF but not in the serum suggesting an abnor-
mal intrathecal production by effector B cells 
[64]. In MS, AutoAbs typically target the myelin 
sheath and the axon but some of them may 
also be directed against anti-inflammatory cyto-
kines such as IL-10 [65] as also described in 
patients with other autoimmune diseases [66].
A further role is played by the genetic back-
ground and an overview of the relationships 
between genes, inflammation, and neurode-
generation has been published by Hauser et al. 
[67]. The strongest genetic association is with 
the Class II allele HLA-DRB1*1501 (DR15) that 
increases the risk of MS by about 3 folds [68]. 
The identification of non-HLA susceptibility loci 
has been elusive for a long time and most asso-
ciations lacked reliable replication in different 
patient cohorts. These inconsistent results 
might be ascribed to the small phenotypic 
effect of these loci conferring marginal risk val-
ues that only extremely large patient and con-
trol datasets have the statistical power to 
detect. Moreover, weak risk factors may have 
different penetrance in different populations 
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exposed to different genetic and environmental 
backgrounds. These problems have been part-
ly overcome by the genome wide association 
studies (GWAS), which scanned the whole 
genome in large patient and control datasets 
and detected several consistent associations 
of MS with multiple genes involved in the 
immune function [69].
Experimental Autoimmune Encephalomyelitis 
(EAE) is the animal model of MS induced using 
CNS homogenates, myelin proteins, or their 
encephalitogenic peptides in adjuvants [70]. 
Most MS patients display an initial inflammato-
ry phase characterized by relapse remitting 
course (RR) and a subsequent phase of sec-
ondary progressive neurodegeneration (SP 
course) [71]. Demyelination is present in both 
phases but it appears to be the consequence 
of different pathogenic mechanisms, since RR 
MS is mainly an inflammatory disease, whereas 
SP MS shows features of neurodegeneration. 
To investigate the relationship between inflam-
mation and neurodegeneration, Tsunoda et al. 
developed an experimental animal model of 
EAE in which the MOG92-106 peptide is used to 
induce EAEs with either the RR or the progres-
sive course using SJL/J and A.SW mice respec-
tively [72]. Histological analysis of the RR form, 
induced in SJL/J mice, shows mild demyelinat-
ing areas around the perivascular cuffs in the 
presence of substantial perivascular T cell infil-
tration. On the contrary, analysis of the progres-
sive form, induced in A. SW mice, shows large 
plaque-like demyelinating areas in the pres-
ence of substantial immunoglobulin deposi-
tion, large numbers of neutrophils and macro-
phages, but minimal T cell infiltration. These 
striking differences might be ascribed to the 
different patterns of immune response, since 
pro-inflammatory Th1 and Th17 cells would 
cause the RR picture, whereas Th2 cells favour-
ing production of myelinotoxic antibodies would 
cause the progressive picture. In conclusion, it 
appears that, although inflammation and neu-
rodegeneration are constantly present in MS, 
different combination of these two mecha-
nisms may lead to the different disease 
courses. 
Myeloid microvesicles may serve as markers of 
neuroinflammation [73]. Microvesicles (MVs) 
are mediators of intercellular communication 
and the activation of microglia and macro-
phages has been associated to their release as 
vehicles for pro-inflammatory signals. Intere- 
stingly the levels of myeloid MVs are higher in 
the CSF of MS patients than in age-matched 
controls. Similarly, high MVs levels are detected 
in mice with RR EAE and they correlate with the 
disease course. Moreover, impairment of MV 
shedding protects mice from EAE development, 
which suggests that MVs play a pathogenic 
role. In addition, mice treated with fingolimod, 
an active drug in EAE and MS, showed a signifi-
cant reduction of the MV level in the CSF [73]. 
These results show that MVs could be useful 
targets for successful disease management in 
the future [74].
Inflammation can play an important role in the 
process of remyelination after damage, espe-
cially when oligodendrocyte precursor cells 
(OPCs) are involved [75]. The inoculation of 
these cells in EAE favours the remyelination of 
injured area [76]. OPCs are activated upon tis-
sue lesion, become mature oligodendrocytes 
and participate in reparative processes. This 
capacity seems to be directed by microglia and 
astrocytes trough the production of cytokines 
and chemokines activating OPCs. Among them, 
PDGF-AA and FGF2 play an important role; par-
ticularly, PDGF seems to be able to direct OPCs’ 
migration [77]. Other important chemokines 
are CXCR4 and CXCL12 which can promote 
migration and differentiation of OPCs [78]. 
OPCs activation seems also to be influenced by 
pro-inflammatory cytokines such as IL-1β and 
TNF-α [77]. Indeed, the inhibition or elimination 
of immune cells, such as lymphocytes and 
macrophages, or cytokines, can impair remye-
lination [79], The phagocytic activity of macro-
phages in particular is crucial for remyelination, 
since the permanence of myelin debris is a sig-
nificant obstacle to the repair process [80]. 
Other important contributions to the under-
standing of how inflammation can drive regen-
eration come from the work of Lucchinetti et 
al., who demonstrated that remyelination takes 
place in lesions where macrophages can be 
detected [81]. Moreover, Bieber et al. showed 
that T lymphocytes, both CD4+ and CD8+ cells, 
are necessary for a complete process of remy-
elination [82]. Consistently, remyelination after 
an acute episode is more represented where 
inflammatory activity is more expressed [21] 
and the injection of T cells specific for myelin 
basic protein (MBP) showed regenerative prop-
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erties in rats with experimental optic nerve 
injury [83].
A potentially neuroprotective role is also played 
by neurotrophins produced by immune cells 
[21]. In the RR form of MS, neurotrophins con-
centrations are higher during the relapse and 
recovery phases than in both the stable phase 
of the disease and progressive forms of MS 
[84]. A particularly interesting neurotrophin is 
the brain derived neurotrophic factor (BDNF) 
produced by myelin reactive T cells, that was 
shown to promote axonal remyelination and oli-
godendrocytes proliferation after experimental 
injury [85]. BDNF can also mediate the effects 
of MS pharmacological therapy (GA and IFNβ) 
due to its capacity of enhancing the prolifera-
tion of Th2 cells, thus promoting an anti-inflam-
matory activity. Consistently, a higher concen-
tration of neurotrophins, such as BDNF, was 
detected in T lymphocytes infiltrating injured 
areas of the CNS in an EAE murine model, sug-
gesting a possible neuroprotective role [86]. 
Moreover, deficiency of neurotrophins, in par-
ticular neurotrophin 3, may be associated to 
brain atrophy in patients with MS [87]. 
One of the most promising therapeutic 
approach in MS, involves immune modulation 
through active or passive immunotherapy. The 
first vaccine experimented in rats against EAE 
was composed of T cell recognizing regions of 
autoantigens to myelin. The rationale was that 
T cells against MBP can induce the production 
of pro-inflammatory cytokines leading to inflam-
mation activation and myelin destruction [88]. 
The first clinical trial with antigen specific immu-
notherapy started in the 1990s with the admin-
istration of bovine myelin in patients with MS, 
but Phase III of the trial did not show positive 
data [89]. Therefore other approaches were 
tried: subcutaneous injection of MBP derived 
peptides, with no positive results, and i.v. 
administration of a synthetic peptide, presently 
on trial, which seems able to reduce the con-
centration of auto-antibody against MBP. In 
1997 Ramshaw et al. obtained tolerance induc-
tion and downregulation of autoimmune activi-
ty by administrating MBP by gene transfer tech-
nology (DNA vaccination). This resulted in the 
activation of Th2-modulated inflammatory 
response, which is anti-inflammatory [90]. In 
2000, Correale et al. used T cells stimulated 
with bovine myelin to treat patients with pro-
gressive MS obtaining a significant reduction of 
T cells reacting against myelin [91]. A DNA vac-
cine currently on trial (BHT-3009), encodes for 
the whole MBP molecule. It has been demon-
strated to be safe and well tolerated, able to 
reduce the amount of MRI contrast-enhancing 
lesions and the concentration of auto-antibod-
ies against MBP and other myelin-specific anti-
gens [89, 92]. Other vaccines under evaluation 
are composed by proteins obtained by fusion of 
cytokines and neuroantigens, such as GMCFS 
+ MOG or MBP; IFNβ + PLP were able to reduce 
the progression of a subsequently induced EAE 
or, if administrated before, to prevent or attenu-
ate it [93]. Mokhtarian et al. used E2 peptide in 
rats infected with Semliki Forest virus, a pep-
tide which seemed to be involved in improving 
remyelination. In these rats, they demonstrated 
a higher remyelinating activity thanks to its 
capacity of activating astrocytes. However, the 
exact mechanism by which it induces remyelin-
ation is not yet clear [94]. Fissolo et al. used a 
vaccine encoding MOG and showed a reduction 
of pro-inflammatory cytokines, the down-regu-
lation of genes involved in inflammation and 
the activation of regulatory T cells. In addition, 
this study showed an activation of neuroprotec-
tive genes such as BDNF and Nft5 and the 
reduction of active MRI lesions [95]. In conclu-
sion DNA vaccines are the most studied in mul-
tiple sclerosis thanks to their ability to induce 
tolerance and modulate the inflammatory 
response by activating anti-inflammatory loops. 
Alzheimer’s disease (AD)
Alzheimer’s disease is the most common cause 
of dementia in the elderly. Clinically, it is char-
acterized by cognitive impairment and, in later 
stages, neuropsychiatric disorders. The typical 
neuropathological findings are represented by 
extracellular β-amiloid plaques (Aβ) and intra-
cellular neurofibrillary tangles (NFTs) mainly 
composed by abnormally phosphorylated 
microtubule-associated protein tau (τ) [96]. 
Substantial evidence demonstrates that the 
anomalous processing of amyloid precursor 
protein (APP) by secretase enzymes causes 
accumulation of insoluble Aβ resistant to prote-
olysis, with consequent neurotoxic effects. 
About 5-10% of AD cases are familiar, related to 
mutations of the APP gene or of the presenil-1 
and presenil-2 genes (PSEN1 and PSEN2) and 
are characterized by early onset (i.e. before the 
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age of 65). PSEN1 and PSEN2 mutations lead 
to a functional modification of the enzyme 
γ-secretase, leading to production of higher 
quantities of Aβ [96].
Aβ deposition in the brain has been shown to 
be associated to an inflammatory response 
with increased levels of pro-inflammatory cyto-
kines, complement components and acute-
phase proteins [97].
On the one hand, there is general agreement 
on considering this inflammatory response 
mainly detrimental, especially when microglia 
displaying the proinflammatory M1 phenotype 
is involved, but the role of the innate immune 
system cells appears to be quite complex [97]. 
Microglial cells act through pattern-recognition 
receptors (PRRs), a conserved group of recep-
tors including Toll-like receptors (TLRs) which 
bind conserved molecular motifs displayed by 
pathogen-associated molecular patterns 
(PAMPs) expressed by infectious agents or 
endogenous danger-associated molecular pat-
terns (DAMPs) released from damaged tissues. 
Microglia and astrocytes can express various 
TRLs [98] that, once bound to their ligands, can 
stimulate the production of pro-inflammatory 
cytokines such as TNF-α and IL-6 and chemo-
kine such as CXCL8 [99]. Interestingly, Aβ and 
microtubule-associated protein τ are among 
the many DAMPs identified. In vivo, activated 
microglia can be found around neurons show-
ing Aβ accumulation [99] and in vitro Aβ can 
induce the expression of TLR2 and TLR4 on 
microglia [100, 101].
On the other hand, it is known that an impor-
tant role of microglia in the CNS is to clear 
apoptotic cells and debris and evidence has 
shown that microglia contributes to the remov-
al of fibrillar Aβ through macropinocytosis, a 
process that depends on actin polymerization 
and microtubule depolarization [102]. Nonethe- 
less, the mechanism by which cells can inter-
nalize fibrillar Aβ has not been fully character-
ized. Different hypotheses have been proposed 
so far. One is use of a receptor group including 
B-class scavenger receptor CD36, α6β1 integ-
rin and the integrin associated protein CD47 
[103]. Another hypothesis involves the action of 
the low-density receptor related protein LRP-1, 
that was demonstrated to reduce the amyloid 
plaques burden and improve cognitive perfor-
mances in a murine model; furthermore the 
blood concentration of such protein was found 
to be reduced in AD patients [104]. However, 
macropinocytosis is not an exclusive function 
of microglia: neurons and astrocytes can also 
internalize fibrillar Aβ, although to a lesser 
extent. Together with microglia, a large number 
of astrocytes can be found surrounding Aβ 
plaques and their role is likely to be relevant in 
clearing these deposits [105]. Astrocyte migra-
tion is mediated by chemoattractive molecules 
such as monocyte chemoattractant protein-1 
(MCP1, also known as CCL2), which is also 
involved in microglia migration and prolifera-
tion [106]. Further evidence on the importance 
of phagocytosis comes from the work by Jaeger 
et al. who demonstrated that AD rats showed 
decreased levels of the protein Beclin 1, which 
is involved in the first stages of Aβ clearance 
[107]. 
Cytokine production by innate immune cells is 
also a key factor in AD pathogenesis. IL-1 is a 
pleiotropic pro-inflammatory cytokine implicat-
ed in several chronic degenerative diseases. 
The IL-1 gene cluster is localized on the long 
arm of chromosome 2 and includes the genes 
coding for IL-1α, IL-1β and IL-1Ra (receptor 
antagonist). In AD, IL-1β is expressed by microg-
lia around Aβ deposits and this seems to be 
involved in the formation of amyloid plaques 
[108]. Variants of the IL-1 gene have been found 
to be associated to AD development [109]. 
Furthermore, IL-1 production is increased after 
trauma or during aging and it is known to stimu-
late expression and processing of APP in neu-
rons [110]. It should be noted that the role of 
APP may not be limited to provide the substrate 
for Aβ accumulation. APP also plays an impor-
tant role in CNS development, in terms of cel-
lular differentiation and synapsis establish-
ment [111]. In the adult brain, APP could be 
involved in neuronal growth and survival, as it 
is expressed in response to cellular injury [112, 
113]. Other important mechanisms mediated 
by IL-1 are the induction of S100β protein 
expression in astrocytes [114], the phosphory-
lation of τ protein [115] and the increase in pro-
duction and activity of acetylcholinesterase 
(AchE) [116]. In particular, S100β has been 
connected to dystrophic neurite growth [117] 
which in turn enhances neuronal expression of 
APP [118] which stimulates the production of 
further S100β. S100β also stimulates intracel-
lular calcium influx, a deadly event for neurons, 
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and production of IL-1β [119] and other pro-
inflammatory cytokines such as IL-6 [120]. This 
vicious circle maintains itself since increased 
levels of APP lead to the production of Aβ with 
microglia activation and further expression of 
IL-1β. The final event is neuronal death, inevita-
bly followed by enhancement of the inflamma-
tory context [112]. Other inflammatory mole-
cules, such as IL-6, α1-antichymotrypsin and 
C-reactive protein, were reported to play a role 
as risk factor for AD development [121, 122]. 
Interestingly, a detrimental role of OPN was 
also demonstrated in AD: where OPN levels 
were reported to be higher in the CSF of AD 
patients compared to controls, with a more 
marked increase in the early stages of the dis-
ease (≤2 years). Moreover, in the same report, 
OPN levels were shown to correlate with cogni-
tive decline [123]. Furthermore, proteomic 
studies showed that OPN levels are higher in 
CSF samples of patients with mild cognitive 
impairment evolving to AD than in the non-
evolving ones [124] and also that presymptom-
atic subjects carrying familial AD mutations dis-
played a significant OPN upregulation [124].
A fundamental contribution to the understand-
ing of neuroinflammation in AD has been pro-
vided by animal models [125]. Transgenic mice 
overexpressing APP or τ protein, knock-in mice 
for mutated PSEN, and triple transgenic mice 
(3xTg-AD mice) overexpressing all three of the 
above have been developed. These animals 
show not only Aβ plaques and NFTs, but also 
the associated inflammatory changes [125]. 
Consistently, AD animal models can provide 
insight into therapeutic strategies aimed at 
modulating neuroinflammation. For instance, 
Kitazawa et al. were able to obtain a beneficial 
effect both on cognition and on pathology by 
blocking IL-1β signaling in 3xTg-AD mice [126]. 
Conversely, the focus of other reports has been 
the beneficial function of cytokines in AD. 
Macrophage colony-stimulating factor (M-CSF) 
was shown to activate the phagocytic activity of 
microglia, thus exerting a protective function 
[127]. This notion is supported by the finding of 
lower concentration of M-CSF in patients with 
mild cognitive impairment converting to AD 
compared to stable MCI patients [128]. Another 
cytokine, IL-34, which is produced by neurons 
and induces macrophages and monocytes pro-
liferation, may have a neuroprotective function 
since it seems to be able to attenuate oligomer-
ic Aβ toxicity [129]. Microglial phagocytosis can 
be stimulated through the signaling pathway of 
TLR4, the expression of which, as already men-
tioned, is induced by Aβ deposition [100, 101]; 
such stimulation ultimately leads to amyloid 
clearing [130]. Milk Fat Globule Factor-E8 
(MFG-E8, also known as lactadherin) is a pro-
tein secreted by microglia that was reported to 
have a role in the clearance of apoptotic neu-
rons [131]. Consistently, Boddaert et al. found 
that its expression is decreased in the brain of 
patients with AD, suggesting that a disregula-
tion of this process may be involved in disease 
development [132]. 
The complement system is an essential compo-
nent of immunity, involved in cytolysis, phago-
cytosis and promotion of inflammation. 
Although the brain is isolated from the external 
environment by the BBB, the complement sys-
tem seems to play a role in both acute and 
chronic neurological diseases, such as AD 
[133]. Evidence indicates that complement 
components can enter the CNS in case of BBB 
disruption but also that they can be locally pro-
duced by microglia, astrocytes and neurons, if 
appropriately stimulated by cytokines [134, 
135]. Whether complement activity is detri-
mental or protective is still a matter of debate. 
Increased expression of receptors for anaphyl-
atoxins C3a and C5a has been documented in 
AD, suggesting that these molecules may drive 
inflammation in this disorder [136, 137]. 
Furthermore, complement components have 
been demonstrated in senile amyloid plaques 
and NFTs [138]. Given such conditions, the 
complement system is thought to be responsi-
ble for neurodegeneration through the induc-
tion of neuronal apoptosis, the production of 
pro-inflammatory cytokines and neuronal cell 
lysis [133].
An increasing number of reports point to a pro-
tective role of complement in AD. It was demon-
strated, for example, that C5a can protect 
human neuroblastoma cells against toxicity 
mediated by Aβ peptide [139]. Anaphylatoxins 
may exert a relevant role in complement-medi-
ated neuroprotection [140]. In an animal model 
of NMDA-mediated cerebral damage, C3a was 
shown not to be involved in the apoptosis path-
way but rather to play a protective role that was 
inhibited when antibodies against C3a were 
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injected into the rat’s brain [133]. Furthermore, 
authors postulated that this protective role may 
depend on the presence of astrocytes. 
Inhibition of C3 and C5 [141], but also of C1q 
fraction, increases amyloid accumulation [142, 
143]. Other beneficial effects mediated by 
complement components are related to anti-
inflammatory cytokines production, clearance 
of apoptotic cells and induction of cell survival 
[133]. 
Starting from the concept of amyloid accumula-
tion as a central component of neurotoxicity in 
AD, the last twenty years saw a significant effort 
focused on modulating immunity against Aβ. 
The first vaccine for Alzheimer’s disease, known 
as AN1792, was composed of immunogenic 
fibrillar Aβ42 extracted from amyloid plaques 
and an adjuvant (SQ21). The vaccine induced 
the synthesis of antibodies against Aβ compo-
nent in the brain of AD patients and the reduc-
tion of Aβ deposits if administered before the 
cerebral deposition of amyloid plaques [144]. 
Since the adjuvant may act as a powerful acti-
vator of Th1 lymphocytes, about 6% of immu-
nized patients developed autoimmune menin-
goencephalitis that led to death in some cases 
[145]. Although autopsies of immunized 
patients provided evidence of deposits clear-
ance, minor clinical benefit was observed and 
no change in survival or in time to severe 
dementia was detected when comparing the 
active to the placebo arm [146].
A second generation of vaccines, aimed at 
inducing a humoral rather than a cellular 
immune response, is currently under investiga-
tion [147]. Preliminary findings suggest a good 
safety profile, even though a strong and unbeat-
able effect on cognition was not detected, rais-
ing criticism toward the so called “Amyloid 
hypotheisis”. Other promising, yet under trial, 
approaches point to passive immunization with 
anti-amyloid monoclonal antibodies [147]. 
Regarding the possibility of either active or pas-
sive immunization against τ protein, interesting 
preliminary findings were obtained in experi-
mental AD models, mainly demonstrating pro-
duction of anti- τ antibodies and histopathologi-
cal improvement [148].
Parkinson’s disease (PD)
PD is a chronic progressive neurodegenerative 
disease, which is clinically characterized by 
tremor, rigidity and bradykinesia and is caused 
by the loss of dopaminergic neurons in the pars 
compacta of the midbrain substantia nigra. In 
later disease stages, autonomic and neuropsy-
chiatric dysfunctions may be present. PD is the 
second most common neurodegenerative dis-
order after AD and age at onset is generally 
between 50 and 60, but 5-10% of patients can 
already show signs of the disease between 20 
and 40. Rare forms can occur before the age of 
30 ( juvenile PD) [149]. The typical pathological 
finding at a macroscopic analysis is the pallor 
of the substantia nigra which corresponds, at a 
microscopic level, to the loss of neurons asso-
ciated to gliosis at this site. Some of the surviv-
ing neurons can show single or multiple round 
intracytoplasmic inclusions, called Lewy bod-
ies, mainly constituted by abnormally aggregat-
ed α-synuclein. The etiology of PD is still 
unknown and several pathogenetic hypotheses 
have been explored. The role of toxic products 
in the destruction of dopaminergic neurons has 
been investigated in relation to the cases of PD 
secondary to exposure to MPTP (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine), the pre-
cursor of MPP+ (1-methyl-4-phenylpyridinium), 
which causes a selective damage of these neu-
rons. Similar molecules are present in herbi-
cides and are now generally considered non-
specific risk factors for PD. Moreover, about 5% 
of PD patients show genetic mutations in spe-
cific genes which can be transmitted as either 
an autosomal dominant or an autosomal reces-
sive trait. Nonetheless, PD appears to be in 
most cases sporadic and multifactorial.
The role of inflammation in PD has been sug-
gested over the last 20 years by a number of 
studies, showing microglia activation, cytokine 
production and oxidative damage in vivo and 
post-mortem [150]. Lewy bodies can induce a 
M1 microglia phenotype, therefore activating a 
pro-inflammatory activity [151]. An interesting 
point is that not all the dopaminergic neurons 
of the substantia nigra degenerate at the same 
time. In particular, the lateral tier of the sub-
stantia nigra degenerates earlier and more 
severely than the more medial nigral compo-
nent. To investigate a potential role of inflam-
mation in this process, Duke et al. compared 
the expression of genes encoding pro-inflam-
matory cytokines and subunits of the mito-
chondrial electron transport chain in these two 
regions in PD patients and healthy controls. 
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Results indicated an increase in the expression 
of such genes together with a reduced expres-
sion of glutathione-related genes in the lateral 
tier of the substantia nigra of PD patients [152]. 
It is known that mitochondrial dysfunction has 
a pathogenic role in PD, as cases of autosomal 
recessive PD can be due to the loss of function 
of either DJ-1 or PINK1, both involved in mito-
chondrial reactions. Interestingly, some of the 
genes studied by Duke et al. are known to be 
highly expressed by glial cells. Accordingly, the 
inflammatory reaction in the substantia nigra 
may play a decisive role in the loss of dopami-
nergic neurons. Furthermore, two characteris-
tics of midbrain dopaminergic neurons must be 
taken in consideration. Unlike hippocampal 
and cortical neurons, these neurons show high 
responsiveness to death-inducing properties of 
molecules such as TNF-α [153] and are located 
in one of the brain regions with the highest den-
sity of microglia [154]. An intriguing theory is 
that external or “internal” harmful stimuli (τ pro-
tein aggregates? Herbicides?) may trigger an 
inflammatory response which, uncontrolled, 
could lead to neurodegeneration. 
Adaptive immune system also seems to play a 
role in PD. Brochard et al. demonstrated the 
presence of CD4+ and CD8+ T lymphocytes, 
but not B lymphocytes, in the substantia nigra 
of MPTP-intoxicated mice and post-mortem 
human brains. The same study also evidenced 
an important reduction of MPTP-mediated neu-
ronal loss in absence of mature T cells in Rag1-
/- and Tcrb-/- immunodeficient mice and sug-
gested a primary role for CD4+ lymphocytes 
and FasL expression [155]. Further studies 
have explored the role of α-synuclein in the acti-
vation of microglia and neurotoxic responses by 
CD4+ T cells [156]. On the contrary, CD4+ regu-
latory T cells seem to induce microglia apopto-
sis [157]. This balance between pro- and anti-
inflammatory activities may be a specific target 
for treatment although it is evident that the sce-
nario is still complex and highly interde- 
pendent. 
Regarding the potential neuroprotective role of 
anti-inflammatory cytokines, it was shown that 
the introduction of complementary DNA for 
IL-10 through a viral vector was able to attenu-
ate dopaminergic cell loss and dopamine (DA) 
striatal deficiency in a rat model of PD [158]. 
Furthermore, Quian et al. demonstrated that 
IL-10 can attenuate microglia activation, with 
decrease of pro-inflammatory factors release, 
such as TNF-α, NO and ROS, and consequent 
reduction of damage to dopaminergic neurons 
[159]. Other studies confirmed a role of IL-10 in 
reducing neuronal death, but did not confirm its 
ability to reduce microglial production of inflam-
matory molecules [160]. Infusion of IL-10 in a 
PD rat model, led to a decrease of both neuro-
nal death and microglial cytokine release [161]. 
IL-6, a cytokine known for mediating pro-inflam-
matory processes, displayed neuroprotective 
activity in PD animal models. In fact, IL-6 defi-
cient mice displayed increased MPTP-induced 
neuronal loss compared to wild type animals. 
These authors were also able to show that 
astrocytes in the striatum are a possible IL-6 
source [162]. In line with these findings, an in 
vitro study by Spittau et al. recently showed 
that IL-6 administration can rescue mesence-
phalic cells from damage previously induced by 
MPP+ [163]. 
Another molecule with a possible anti-inflam-
matory role is the vasoactive intestinal peptide 
(VIP). Administration of VIP in mice with MPTP-
induced PD decreased not only IL-1β and TNF-α 
expression in the substantia nigra and striatum 
but also striatal cells degeneration [164]. 
Furthermore, in human neuroblastoma cells 
and rat cerebellar granular cells, VIP can pre-
vent neuronal loss by enhancing cellular ability 
to resist oxidative stress [165]. The dual role of 
cytokines (detrimental versus protective) may 
also show some relationship with their concen-
tration in the substatia nigra. For instance, in 
adult mice, chronically low concentration of 
TNFα can be protective for neuronal loss and 
this effect can be mediated by other molecules 
such as TNFα receptors 1 (TNFR1), glial cell 
line-derived neurotrophic factor (GDNF) and 
IGF1 [166]. 
The cytokine OPN has also been studied in PD, 
where it was shown that its expression was 
decreased in surviving dopaminergic neurons 
[167]. Moreover, the OPN fragment contaning 
the RGD- binding domain was shown to protect 
TH-positive cells against toxic insult induced by 
MPP+ and LPS in vitro, thus suggesting that 
this peptide may fovor the survival of dopami-
nergic cells in presence of a toxic insult [168]. 
Nonetheless, another study showed that OPN 
knockout mice exposed to MPTP displayed less 
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nigral cell death and a decreased glial response 
compared to wild-type mice. In the same report, 
it was shown that OPN serum and CSF levels 
were higher in PD patients than controls, with 
CSF levels positively correlated with concomi-
tant dementia [169].
Taken together, these observations suggest 
that OPN may act as a double-edged sword trig-
gering neuronal toxicity and death in some con-
texts and functioning as a neuroprotectant in 
others. 
A neuroprotective role in PD is also played by 
CD4+CD25+ regulatory T cells (Tregs). Tregs 
can downmodulate the pro-inflammatory activ-
ity of microglia and reduce microglia activation 
after injuries and its production of ROS [170, 
171]. Moreover, Tregs attenuate the activity of 
pro-inflammatory and detrimental proinflam-
matory Th17 cells [172]. 
The presence of protein deposits in PD led to 
explore the use of immunotherapy for PD, too. 
In this case, the target was α-synuclein, the 
principal component of Lewy bodies [173]. Both 
active and passive immunization approaches 
were tried in animals. Vaccinated mice pro-
duced anti-α-synuclein antibodies and dis-
played decreased protein aggregates and 
improvement of neurodegeneration [174]. 
Similar biochemical and neuropathological 
findings were obtatained by the same group by 
passive immunization with an anti-α-synuclein 
monoclonal antibody. In this case, a behav-
ioural improvement was also noted [175]. In 
2010, a pre-clinical study was started to evalu-
ate the efficacy of a vaccine against the phos-
phorilated form of α-synuclein, which seems to 
be involved in activating an inflammatory 
response [176]. The first-in-humans clinical trial 
is currently on-going, and it points at assessing 
safety and tolerability of this approach.
A further immunotherapeutic approach was 
proposed by Benner and colleagues who used 
the MTPT mouse model to assess the effect of 
treatment with copolimer 1 (Cop1), an amino 
acid polymer that induces development of non-
encephalitogenic lymphocytes reacting against 
basic myelin protein and promotes the differen-
tiation of anti-inflammatory Th2 lymphocytes. 
The results of this study showed how Cop1 
accumulated in the cerebral areas with a high-
er degenerative damage and led to an increase 
of neurotrophic factors in the midbrain [177]. 
Another potentially interesting strategy involves 
activation of Tregs which are able to stimulate 
the production of trophic factors by astrocytes 
[176].
The time factor of neuroinflammation in AD 
and PD
Epidemiological studies indicate that long-term 
use of non-steroidal anti-inflammatory drugs 
(NSAIDs) has a protective effect and significant-
ly lowers the risk of developing AD later in life 
[178] and similar results were obtained in PD 
[179, 180].
These findings encouraged clinical trials explor-
ing whether NSAIDs administration would 
affect AD or PD progression. Unfortunately, 
such trials provided disappointing results [181, 
182].
The main reason for such discrepancy would be 
related to the timing of NSAIDs administration. 
Indeed, when a neurodegenerative disease is 
diagnosed, neuronal loss is already advanced 
and the molecular processes driving disease 
evolution are likely different from those favor-
ing the initial development of the disease. As 
discussed above, the time-line of immune sys-
tem involvement in neurodegenerative diseas-
es is probably characterized by phases in which 
inflammation is detrimental, with a predomi-
nant involvement of proinflammatory M1 
microglia and Th1-Th17 cells, alternated with 
phases in which the anti-inflammatory network 
prevails.
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